Indaptus Therapeutics, Inc. (INDP) Stock Price & Analysis
Indaptus Therapeutics, Inc. (INDP) closed at USD 3.16 on Friday, October 23, 2026, up 5.69% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.99; the Oct 23, 2026 session ranged USD 2.87–3.22 on volume of 287,477 shares. Market capitalization is $421.05M, with a 52-week range of USD 0.92–5.96 (NCM). Source: Nexqual, retrieved October 24, 2026 at 13:34 UTC.
Also available as compact Markdown for AI agents: nexqual.com/INDP.md
Key facts (INDP)
- Analysts: None.
- Total return with dividends: 1Y -12.9% vs S&P 500 +13.4%; 5Y -98.4% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (INDP)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$7.7M | -$14.9M | -$16.4M | -$15.4M | -$19.8M | -$14.8M |
| Net income | -$7.7M | -$14.3M | -$15.4M | -$15.0M | -$20.8M | -$15.4M |
| EPS (diluted) | -$52.92 | -$48.44 | -$51.24 | -$44.96 | -$21.58 | — |
| Free cash flow | -$11.3M | — | — | — | — | — |
| Cash + short-term investments | $39.1M | $26.4M | — | — | $8.5M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (INDP)
P/B 37.0x · Earnings yield -3.66%
Analysts (INDP)
Consensus None.
Total return (dividends reinvested) (INDP)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -12.9% | -98.4% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -13.0% | -56.4% |
| Volatility (annualized) | 182.7% | 113.9% |
| Max drawdown | -80.3% (Jun 2026→Aug 2026) | -99.5% (Nov 2021→Aug 2026) |
INDP suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Merck (MRK) | “at Merck Research Laboratories, including external research, out-licensing regional deals, and academic alliances.” |
Quoted from the company's 10-K filed Mar 17, 2026.
INDP analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Mar 2026) | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2026) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 13:34 UTC)
| Price | USD 3.16 |
|---|---|
| Change | ▲ 5.69% (up) |
| Previous Close | USD 2.99 |
| Open | USD 3 |
| Day Range | USD 2.87 – 3.22 |
| 52-Week Range | USD 0.92 – 5.96 |
| Volume | 287,477 shares |
| Market Cap | $421.05M |
| Exchange | NCM |
Technical Analysis (INDP)
Nexqual's technical model rates INDP "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 24, 2026 at 13:34 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 59.53 (neutral) |
| vs SMA50 | Above (USD 2.33) |
| MACD | 0.12 (positive) |
Analyst Ratings (INDP)
Wall Street analysts rate INDP "None", per Nexqual as of October 24, 2026 at 13:34 UTC.
| Consensus Rating | None |
|---|
Earnings (INDP)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -9.19 vs est -4.36 ▼ miss |
| 2025-09-30 | USD -2.98 vs est -4.17 ▲ beat |
| 2025-06-30 | USD -9.09 vs est -9.24 ▲ beat |
| 2025-03-31 | USD -8.96 vs est -5.04 ▼ miss |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Financials & Fundamentals (INDP)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -318.04% |
| Current Ratio | 19.48 |
| Total Cash | $11.55M |
| Total Debt | $0 |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Financial Health Score (INDP)
Nexqual rates Indaptus Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 13:34 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $12M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$15M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -318%, ROA -98.1% |
Ownership (INDP)
| Insider Ownership | +70.65% |
|---|---|
| Institutional Ownership | +0.26% |
| Shares Outstanding | 133.24M |
| Float | 25.00M |
| Short % of Float | +2.00% |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Leadership (INDP)
Indaptus Therapeutics, Inc. is led by Junyi Dai, CEO & Chairman, per Nexqual as of October 24, 2026 at 13:34 UTC.
| CEO & Chairman | Junyi Dai |
|---|---|
| Chief Financial Officer | Yu Ding |
Major Backers & Investors (INDP)
Notable institutional backers of Indaptus Therapeutics, Inc. include HRT Financial LP, according to Nexqual as of October 24, 2026 at 13:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HRT Financial LP | 0.15% |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
From Indaptus Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- June 2025, we completed a private placement, or the June 2025 Financing, of convertible notes to certain investors, including our then Chief Executive Officer, Jeffrey Meckler, in the aggregate principal amount of approximately $5.7 million and warrants to purchase shares of common stock.
- U.S. the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations, and biologics under the FDCA and the Public Health Service Act (PHSA) and its implementing regulations.
- FDA approval is required before any new unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States.
- We have developed patented treatment methods (and associated patented compositions) for attenuation and killing of non-pathogenic, Gram-negative bacteria.
Partnerships
- December 22, 2025, we entered into the Purchase Agreement with Mr.
- LLC ("Wainwright"), which was amended on September 1, 2022, relating to the offer and sale of shares of our common stock having an aggregate offering price of up to $6.3 million.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 13:34 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt